PR Newswire
SAN DIEGO
,
June 28, 2021
/PRNewswire/ —
Cardiff Oncology, Inc. (Nasdaq: CRDF)
, a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic and castrate-resistant prostate cancer, today announced that it has been added as a member of the small-cap Russell 2000
®
Index, the all-cap Russell 3000
®
Index, and the Russell Microcap
®
Index, effective upon the U.S. market open today,
June 28, 2021
, as part of the 2021 Russell indexes reconstitution.
The 2021 annual reconstitution of the Russell indexes captured the 4,000 largest U.S. stocks as of
May 7, 2021
, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000
®
Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000
®
Index or small-cap Russell 2000
®
Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
$10.6 trillion
in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 3000
®
, Russell 2000
®
and Russell Microcap
®
Indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the
FTSE Russell website
.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin
®
(bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga
®
(abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC); and a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). A Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML) completed enrollment in 2020. For more information, please visit
.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
$17.9 trillion
is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit
www.ftserussell.com
.
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
[email protected]
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
[email protected]
Media Contact:
Amy Jobe
, Ph.D.
LifeSci Communications
315-879-8192
[email protected]
View original content to download multimedia:
https://www.prnewswire.com/news-releases/cardiff-oncology-added-to-the-russell-2000-and-other-ftse-russell-indexes-301320789.html
SOURCE Cardiff Oncology, Inc.
